ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Acquires 150,000 Shares of Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius bought 150,000 shares of the business’s stock in a transaction on Friday, June 26th. The stock was acquired at an average cost of $1.54 per share, for a total transaction of $231,000.00. Following the completion of the transaction, the director owned 150,000 shares in the company, valued at $231,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

ProQR Therapeutics Trading Up 1.6%

PRQR stock opened at $1.86 on Wednesday. ProQR Therapeutics N.V. has a twelve month low of $1.33 and a twelve month high of $3.10. The company has a market capitalization of $195.97 million, a P/E ratio of -3.72 and a beta of 0.07. The firm has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $1.70.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. On average, research analysts predict that ProQR Therapeutics N.V. will post -0.57 EPS for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently bought and sold shares of the business. Osaic Holdings Inc. grew its holdings in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the last quarter. Guggenheim Capital LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth approximately $35,000. Moody Lynn & Lieberson LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth approximately $50,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter valued at approximately $51,000. Finally, Axiom Investment Management LLC acquired a new position in ProQR Therapeutics during the 1st quarter valued at approximately $53,000. Institutional investors own 32.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Oppenheimer initiated coverage on ProQR Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price objective for the company. Weiss Ratings cut ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Chardan Capital reduced their target price on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Finally, Wall Street Zen lowered ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.33.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.